Polymyositis is an autoimmune disease. It belongs to a group of conditions called idiopathic inflammatory myopathies, where the immune system mistakenly attacks the body’s own muscle tissue, causing progressive weakness. It is rare, with an estimated annual incidence of 6 to 10 cases per million people, and it peaks in adults between ages 60 and 69.
How the Immune System Attacks Muscle
In polymyositis, a specific type of immune cell called a CD8+ cytotoxic T cell drives the damage. These cells, along with immune cells called macrophages, surround healthy, non-damaged muscle fibers and eventually invade and destroy them. This is a direct, cell-mediated attack, which distinguishes polymyositis from some other inflammatory muscle diseases where blood vessel damage or antibody-driven injury plays a larger role.
For this attack to happen, muscle fibers begin displaying a surface marker (called MHC class I) that healthy muscle cells don’t normally show. This marker essentially flags the muscle as a target. What triggers this abnormal expression isn’t fully understood, but viral infections are one suspected cause: a virus may infect muscle tissue and release inflammatory signals that make the muscle vulnerable to immune attack. The body also has regulatory immune cells that try to counterbalance the destruction, but in polymyositis, the destructive response overwhelms this protective mechanism.
Symptoms and How They Progress
The hallmark of polymyositis is symmetrical weakness in the muscles closest to the trunk of the body, particularly the shoulders, upper arms, hips, and thighs. You might first notice difficulty climbing stairs, getting out of a chair, lifting objects overhead, or raising your arms to wash your hair. The weakness typically develops gradually over weeks to months rather than appearing suddenly.
Unlike some muscle conditions, polymyositis does not cause a skin rash. This is one of the clearest ways it differs from dermatomyositis, a related autoimmune myopathy that produces distinctive skin changes alongside muscle weakness. Polymyositis also does not typically affect the hands, feet, or facial muscles in its early stages, though swallowing difficulties can develop if the muscles of the throat become involved.
How It’s Diagnosed
Blood tests usually reveal elevated levels of creatine kinase (CK), an enzyme that leaks out of damaged muscle cells. CK levels can rise dramatically during active disease, though levels more than 100 times the normal range are rare. Importantly, CK levels can also be normal in chronic or late-stage cases despite ongoing muscle damage, so a normal result doesn’t rule out active disease.
Doctors also test for myositis-specific autoantibodies, which are immune proteins found in people with autoimmune muscle disease but not in those with genetic or other non-immune muscle conditions. However, polymyositis itself has become a narrower diagnosis over time. At the Johns Hopkins Myositis Center, one of the largest referral centers for these conditions, very few patients out of more than 1,000 ultimately receive a polymyositis diagnosis. Most people initially suspected of having polymyositis turn out to have a different condition: inclusion body myositis (a degenerative muscle disease), immune-mediated necrotizing myopathy (a distinct autoimmune pattern), a genetic muscle disease, or antisynthetase syndrome (defined by the presence of specific antibodies like anti-Jo-1).
A muscle biopsy remains important for confirming the diagnosis. Under a microscope, polymyositis shows inflammatory cells, predominantly CD8+ T cells, infiltrating and surrounding muscle fibers. This pattern differs from dermatomyositis, where the inflammation centers around blood vessels and causes a characteristic thinning of muscle fibers at the edges of fiber bundles.
Treatment and What to Expect
Because polymyositis is driven by an overactive immune system, treatment focuses on suppressing that immune response. High-dose corticosteroids are the standard first-line therapy. This high dose is typically maintained for 4 to 8 weeks until blood markers of muscle damage return to normal, then gradually reduced over months to find the lowest effective dose. Most people notice improvement in strength within the first few months, though recovery is often incomplete.
Many patients need a second immunosuppressive medication added alongside corticosteroids, either to improve the response or to allow a lower steroid dose and reduce long-term side effects like bone thinning, weight gain, and elevated blood sugar. When the disease proves resistant to initial treatment, a therapy called rituximab, which depletes a specific type of immune cell, has shown meaningful results. A large analysis of 26 studies found that about 65% of patients with inflammatory myopathies responded to rituximab, with 45% achieving a complete response. For dermatomyositis and polymyositis specifically, the response rate was 68%.
Treatment is typically long-term. Flares can occur when medications are tapered too quickly, and doctors monitor CK levels alongside physical strength to gauge disease activity. Some people eventually achieve stable remission on low-dose medication, while others require ongoing treatment to maintain function.
How Polymyositis Differs From Related Conditions
The broader category of autoimmune myopathies includes several distinct conditions that can look similar on the surface but differ in their underlying mechanisms, associated antibodies, and treatment responses.
- Dermatomyositis causes muscle weakness plus skin findings like a violet-colored rash on the eyelids or a scaly rash over the knuckles. The immune attack targets blood vessels in the muscle rather than individual muscle fibers directly.
- Immune-mediated necrotizing myopathy features prominent muscle cell death with minimal inflammation. It is associated with anti-SRP or anti-HMGCR antibodies and can sometimes be triggered by cholesterol-lowering medications.
- Antisynthetase syndrome involves muscle inflammation alongside lung disease, joint pain, and specific antibodies like anti-Jo-1. Many patients originally diagnosed with polymyositis are reclassified as having this condition once antibody testing is completed.
- Inclusion body myositis progresses more slowly and preferentially weakens the finger flexors and quadriceps. It responds poorly to immunosuppressive therapy and may have both autoimmune and degenerative components.
Because these conditions overlap in their early presentation, getting the specific diagnosis right matters. Each responds differently to treatment, and some carry distinct risks, like the association between dermatomyositis and certain cancers, that require different monitoring strategies.